Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

Kumi Oshima; Miki Sato; Shinya Okuda; Kiriko Terasako; Hideki Nakasone; Shinichi Kako; Rie Yamazaki; Yukie Tanaka; Aki Tanihara; Takakazu Higuchi; Junji Nishida; Ikuo Nakamura; Yukio Yoshida; Yoshinobu Kanda

doi:10.1179/102453309X385223

Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

Kumi Oshima, Miki Sato, Shinya Okuda, Kiriko Terasako, Hideki Nakasone, Shinichi Kako, Rie Yamazaki, Yukie Tanaka, Aki Tanihara, Takakazu Higuchi, Junji Nishida, Ikuo Nakamura, Yukio Yoshida, Yoshinobu Kanda

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

The appearance of hepatitis B surface antigen (HBsAg) in patients previously positive for antibody to this antigen (HBsAb) is called reverse seroconversion, a rare complication after hematopoietic stem cell transplantation (HSCT), which occurs almost exclusively after HSCT from an HBsAb-negative donor and the development of chronic graft-versus-host disease (CGVHD). However, we experienced a patient who developed reverse seroconversion 23 months after unrelated HSCT even in the absence of immunosuppressants use or CGVHD. Serum immunoglobulin level was persistently normal. Therefore, all HBsAb-positive recipients should be considered to be at risk for HBV reactivation, even in patients without any risk factors.

Original language	English
Pages (from-to)	73-75
Number of pages	3
Journal	Hematology
Volume	14
Issue number	2
DOIs	https://doi.org/10.1179/102453309X385223
Publication status	Published - 2009
Externally published	Yes

Keywords

Graft-versus-host disease
Hematopoietic stem cell transplantation
Hepatitis B virus
Reverse seroconversion

ASJC Scopus subject areas

Hematology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1179/102453309X385223

Cite this

Oshima, K., Sato, M., Okuda, S., Terasako, K., Nakasone, H., Kako, S., Yamazaki, R., Tanaka, Y., Tanihara, A., Higuchi, T., Nishida, J., Nakamura, I., Yoshida, Y., & Kanda, Y. (2009). Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. Hematology, 14(2), 73-75. https://doi.org/10.1179/102453309X385223

Oshima, K, Sato, M, Okuda, S, Terasako, K, Nakasone, H, Kako, S, Yamazaki, R, Tanaka, Y, Tanihara, A, Higuchi, T, Nishida, J, Nakamura, I, Yoshida, Y & Kanda, Y 2009, 'Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease', Hematology, vol. 14, no. 2, pp. 73-75. https://doi.org/10.1179/102453309X385223

@article{e4149de09dac46dc9dd974f7b2e7e8b9,

title = "Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease",

abstract = "The appearance of hepatitis B surface antigen (HBsAg) in patients previously positive for antibody to this antigen (HBsAb) is called reverse seroconversion, a rare complication after hematopoietic stem cell transplantation (HSCT), which occurs almost exclusively after HSCT from an HBsAb-negative donor and the development of chronic graft-versus-host disease (CGVHD). However, we experienced a patient who developed reverse seroconversion 23 months after unrelated HSCT even in the absence of immunosuppressants use or CGVHD. Serum immunoglobulin level was persistently normal. Therefore, all HBsAb-positive recipients should be considered to be at risk for HBV reactivation, even in patients without any risk factors.",

keywords = "Graft-versus-host disease, Hematopoietic stem cell transplantation, Hepatitis B virus, Reverse seroconversion",

author = "Kumi Oshima and Miki Sato and Shinya Okuda and Kiriko Terasako and Hideki Nakasone and Shinichi Kako and Rie Yamazaki and Yukie Tanaka and Aki Tanihara and Takakazu Higuchi and Junji Nishida and Ikuo Nakamura and Yukio Yoshida and Yoshinobu Kanda",

year = "2009",

doi = "10.1179/102453309X385223",

language = "English",

volume = "14",

pages = "73--75",

journal = "Hematology",

issn = "1024-5332",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

AU - Oshima, Kumi

AU - Sato, Miki

AU - Okuda, Shinya

AU - Terasako, Kiriko

AU - Nakasone, Hideki

AU - Kako, Shinichi

AU - Yamazaki, Rie

AU - Tanaka, Yukie

AU - Tanihara, Aki

AU - Higuchi, Takakazu

AU - Nishida, Junji

AU - Nakamura, Ikuo

AU - Yoshida, Yukio

AU - Kanda, Yoshinobu

PY - 2009

Y1 - 2009

N2 - The appearance of hepatitis B surface antigen (HBsAg) in patients previously positive for antibody to this antigen (HBsAb) is called reverse seroconversion, a rare complication after hematopoietic stem cell transplantation (HSCT), which occurs almost exclusively after HSCT from an HBsAb-negative donor and the development of chronic graft-versus-host disease (CGVHD). However, we experienced a patient who developed reverse seroconversion 23 months after unrelated HSCT even in the absence of immunosuppressants use or CGVHD. Serum immunoglobulin level was persistently normal. Therefore, all HBsAb-positive recipients should be considered to be at risk for HBV reactivation, even in patients without any risk factors.

AB - The appearance of hepatitis B surface antigen (HBsAg) in patients previously positive for antibody to this antigen (HBsAb) is called reverse seroconversion, a rare complication after hematopoietic stem cell transplantation (HSCT), which occurs almost exclusively after HSCT from an HBsAb-negative donor and the development of chronic graft-versus-host disease (CGVHD). However, we experienced a patient who developed reverse seroconversion 23 months after unrelated HSCT even in the absence of immunosuppressants use or CGVHD. Serum immunoglobulin level was persistently normal. Therefore, all HBsAb-positive recipients should be considered to be at risk for HBV reactivation, even in patients without any risk factors.

KW - Graft-versus-host disease

KW - Hematopoietic stem cell transplantation

KW - Hepatitis B virus

KW - Reverse seroconversion

UR - http://www.scopus.com/inward/record.url?scp=66949138644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66949138644&partnerID=8YFLogxK

U2 - 10.1179/102453309X385223

DO - 10.1179/102453309X385223

M3 - Article

C2 - 19298717

AN - SCOPUS:66949138644

SN - 1024-5332

VL - 14

SP - 73

EP - 75

JO - Hematology

JF - Hematology

IS - 2

ER -

Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this